ImmuCell Corporation — Q1 2022 Form 10-Q
Business context and period. Unaudited results for the three months ended March 31, 2022, compared with Q1 2021. ImmuCell develops and sells animal-health products. First Defense, for preventing scours in newborn calves, generated nearly all revenue; Re-Tain, a treatment for subclinical mastitis in dairy cows, remained in development and had no sales.
Financial results and condition
- Revenue: Product sales were $6.00 million, up 46% from $4.11 million. U.S. sales rose 54%; international sales declined 8% and represented 8% of sales.
- Profitability: Gross profit was $3.10 million versus $1.60 million; gross margin was 52% versus 39%. Operating income was $793,000 versus an operating loss of $375,000. Net income was $736,000, or $0.10 basic and $0.09 diluted per share, versus a net loss of $441,000, or $0.06 per share.
- Expenses and margins: Operating expenses increased 17% to $2.31 million, including sales and marketing costs up 56% to $812,000. Product development expense was approximately $1.04 million, broadly unchanged. Management cautioned that Q1’s 52% gross margin may not be repeatable.
- Cash flow: Operating activities provided $639,000, compared with $624,000 used in Q1 2021. Capital expenditures were $807,000, primarily for manufacturing expansion; operating cash flow less capital expenditures was approximately negative $169,000. Financing activities provided $1.79 million, including $2.00 million of new mortgage borrowing. Cash increased $1.63 million to $11.82 million.
- Liquidity and debt: Current assets were $18.30 million and current liabilities $2.35 million; net working capital was $15.95 million. Debt obligations, net of issuance costs, totaled $10.93 million at quarter-end, up from $9.14 million at December 31, 2021. The company had no outstanding balance on its $1.0 million line of credit. Management said available cash and anticipated product margins should fund planned operations and capital needs for at least 12 months.
- Other balance-sheet data: Total assets were $46.70 million and stockholders’ equity $33.37 million. Inventory increased to $3.44 million from $3.09 million.
Material changes versus Q1 2021
- Sales growth and improved gross margin drove the change from operating and net losses to operating and net income.
- First Defense sales rose to $5.96 million from $4.02 million. The product line accounted for 99% of total sales.
- Operating cash flow improved by approximately $1.26 million, principally reflecting higher net income. Capital expenditures more than doubled to $807,000.
- Debt increased following a $2.00 million mortgage amendment in Q1 2022. The amended mortgage carries a blended fixed rate of 3.53%, with a balloon payment due in 2032.
Outlook, commentary and risks
- First Defense demand and capacity: Management reported a backlog of approximately $1.6 million as of May 6, 2022, down from approximately $2.4 million at December 31, 2021. It attributed constraints to strong demand, supply-chain disruption, input-cost inflation and production ramp-up. Management targeted annual production capacity of approximately $30 million by September 2022 and $35 million by year-end, subject to production yields, product mix and other factors. Its objective is total annual product sales of approximately $23 million or more by 2023.
- Re-Tain: FDA approval remains a key uncertainty. The company resubmitted its Drug Substance and Drug Product technical section in Q1 2022 and expected an FDA response around August 2022; a Q4 2022 launch was conditional on approval. Management described a controlled launch and estimated approximately $1 million in 2023 sales and about twice that in 2024, assuming launch around the start of Q4 2022. These are forward-looking estimates, not assurances.
- Investment and costs: The company is expanding First Defense capacity and building in-house Re-Tain formulation and aseptic-filling capability. It anticipated FDA approval of the Re-Tain facility by Q2 2024. Management expected annual gross margin of 46%–50% as expanded capacity is utilized, while noting inflation, biological yield variability and higher production costs could affect results.
- Financing and covenant: The bank reduced the minimum debt-service coverage ratio to 1.0 for 2022; management noted projected performance could otherwise have made covenant compliance challenging. Management anticipated approximately $907,000 of debt principal repayments in the 12 months ending March 31, 2023, excluding MTI loans, and approximately $337,000 of interest expense over that period.
- Concentration and external risks: Two distributors accounted for 74% of Q1 sales and 72% of receivables at March 31. The filing cites COVID-related and broader supply disruptions, inflation, labor availability, commodity and transportation costs, dairy-market volatility, competition, and dependence on key suppliers and personnel. Re-Tain also faces regulatory, manufacturing, adoption and milk/cheese-processing risks.
- Other items: The CEO’s amended compensation agreements provide for up to $300,000 of deferred compensation subject to scheduled vesting and employment conditions, and up to $150,000 of incentive compensation subject to 2022 objectives. No material reportable subsequent events or material pending legal proceedings were disclosed. Management reported effective disclosure controls and internal control over financial reporting as of March 31, 2022.
Most important facts for investors to verify
- Whether First Defense capacity expansions meet stated timing and output targets, and whether backlog reduction translates into sustained sales rather than distributor inventory buildup.
- FDA review progress and any inspection findings affecting Re-Tain approval, launch timing, or the planned in-house manufacturing facility.
- Whether gross margin can remain within management’s 46%–50% expected range amid input inflation and variable yields.
- Debt service, compliance with the revised 2022 covenant, and cash needs for committed capital projects and inventory.
- Exposure to the two major distributors and to supply constraints, including any changes in customer concentration or receivable collections.
- Whether Re-Tain’s controlled-launch sales estimates and market-adoption assumptions are achieved; the filing emphasizes substantial regulatory and commercial uncertainty.